Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease
AbstractIntroduction: Treatment strategies in Parkinson’s disease (PD) can improve a patient’s quality of life but cannot stop the progression of PD. We are looking for different alternatives that modify the natural course of the disease and recent research has demonstrated the neuroprotective properties of erythropoietin. In Cuba, the Center for Molecular Immunology (CIM) is a cutting edge scientific center where the recombinant form (EPOrh) and recombinant human erythropoietin with low sialic acid (NeuroEPO) are produced. We performed two clinical trials to evaluate the safety and tolerability of these two drugs in PD patients. In this paper we want to show the positive results of the additional cognitive tests employed, as part of the comprehensive assessment. Materials and method: Two studies were conducted in PD patients from the outpatient clinic of CIREN, including n = 10 and n = 26 patients between 60 and 66 years of age, in stages 1 to 2 of the Hoehn and Yahr Scale. The first study employed recombinant human (rhEPO) and the second an intranasal formulation of neuroEPO. All patients were evaluated with a battery of neuropsychological scales composed to evaluate global cognitive functioning, executive function, and memory. Results: The general results in both studies showed a positive response to the cognitive functions in PD patients, who were undergoing pharmacological treatment with respect to the evaluation (p < 0.05) before the intervention. Conclusions: Erythropoietin has a discrete positive effect on the cognitive functions of patients with Parkinson’s disease, which could be interpreted as an effect of the neuroprotective properties of this molecules. To confirm the results another clinical trial phase III with neuroEPO is in progress, also designed to discard any influence of a placebo effect on cognition. View Full-Text
A printed edition of this Special Issue is available here.
Share & Cite This Article
Pedroso, I.; Garcia, M.; Casabona, E.; Morales, L.; Bringas, M.L.; Pérez, L.; Rodríguez, T.; Sosa, I.; Ricardo, Y.; Padrón, A.; Amaro, D. Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease. Behav. Sci. 2018, 8, 51.
Pedroso I, Garcia M, Casabona E, Morales L, Bringas ML, Pérez L, Rodríguez T, Sosa I, Ricardo Y, Padrón A, Amaro D. Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease. Behavioral Sciences. 2018; 8(5):51.Chicago/Turabian Style
Pedroso, Ivonne; Garcia, Marité; Casabona, Enrique; Morales, Lilia; Bringas, Maria L.; Pérez, Leslie; Rodríguez, Teresita; Sosa, Ileana; Ricardo, Yordanka; Padrón, Arnoldo; Amaro, Daniel. 2018. "Protective Activity of Erythropoyetine in the Cognition of Patients with Parkinson’s Disease." Behav. Sci. 8, no. 5: 51.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.